百花医药
(600721)
| 流通市值：25.47亿 | | | 总市值：25.47亿 |
| 流通股本：3.84亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 96,917,183.06 | 385,755,767.94 | 290,630,947.61 | 196,304,097.42 |
| 营业收入 | 96,917,183.06 | 385,755,767.94 | 290,630,947.61 | 196,304,097.42 |
| 二、营业总成本 | 69,790,602.6 | 293,053,303.13 | 236,012,856.12 | 157,352,200.56 |
| 营业成本 | 47,091,129.13 | 188,295,698.19 | 155,589,054.18 | 102,564,923.99 |
| 税金及附加 | 1,149,557.77 | 5,216,353.99 | 3,721,878.72 | 2,606,022.39 |
| 销售费用 | 2,430,443.29 | 11,368,492.51 | 9,209,043.11 | 6,891,425.52 |
| 管理费用 | 13,236,147.26 | 60,025,107.05 | 46,193,235.34 | 31,980,216.22 |
| 研发费用 | 6,183,247.17 | 29,547,683.22 | 22,270,105.49 | 13,947,010.74 |
| 财务费用 | -299,922.02 | -1,400,031.83 | -970,460.72 | -637,398.3 |
| 其中:利息费用 | - | - | 0 | - |
| 其中:利息收入 | 317,961.66 | 1,465,140.38 | 1,042,753.09 | 692,465.37 |
| 加:公允价值变动收益 | - | -125,000 | - | - |
| 加:投资收益 | 630,163.75 | 3,495,093.54 | 2,560,123.26 | 1,744,495.09 |
| 资产处置收益 | - | 89,534.43 | 86,255.16 | 86,255.16 |
| 资产减值损失(新) | -2,144,716.44 | -43,455,839.69 | -26,424,038.92 | -12,991,463.31 |
| 信用减值损失(新) | -4,041,106.78 | -17,048,933.98 | -4,306,666.11 | -3,379,460.09 |
| 其他收益 | 369,448.68 | 1,378,422.55 | 608,191.12 | 465,992.08 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 21,940,369.67 | 37,035,741.66 | 27,141,956 | 24,877,715.79 |
| 加:营业外收入 | 3,863.15 | 175,456.6 | 113,097.83 | 98,579.81 |
| 减:营业外支出 | 52,708.29 | 346,613.62 | 202,501.4 | 177,265.78 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 21,891,524.53 | 36,864,584.64 | 27,052,552.43 | 24,799,029.82 |
| 减:所得税费用 | 1,170,664.59 | -4,614,458.4 | 3,099,308.23 | 2,138,044.2 |
| 六、净利润 | 20,720,859.94 | 41,479,043.04 | 23,953,244.2 | 22,660,985.62 |
| 持续经营净利润 | 20,720,859.94 | 41,479,043.04 | 23,953,244.2 | 22,660,985.62 |
| 归属于母公司股东的净利润 | 20,720,859.94 | 41,479,043.04 | 23,953,244.2 | 22,660,985.62 |
| (一)基本每股收益 | 0.05 | 0.11 | 0.06 | 0.06 |
| (二)稀释每股收益 | 0.05 | 0.11 | 0.06 | 0.06 |
| 八、其他综合收益 | - | -98,649.55 | - | - |
| 归属于母公司股东的其他综合收益 | - | -98,649.55 | - | - |
| 九、综合收益总额 | 20,720,859.94 | 41,380,393.49 | 23,953,244.2 | 22,660,985.62 |
| 归属于母公司股东的综合收益总额 | 20,720,859.94 | 41,380,393.49 | 23,953,244.2 | 22,660,985.62 |
| 公告日期 | 2025-04-26 | 2025-03-12 | 2024-10-25 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |